logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Feb 2020
CTD Holdings Inc
CTDH.OB
Data from Phase I trial of Trappsol
Niemann-Pick Disease Type C
after Q1 2020
Trevi Therapeutics
Topline data from phase II clinical trial of Nalbuphine ER
Chronic cough in patients with idiopathic pulmonary fibrosis
2020
BioNTech
Data from phase I trial of BNT111
Advanced melanoma
after Q1 2020
BioNTech
Data from phase 1 trial of BNT114
Triple-negative breast cancer
Q1 2020
Tonix Pharmaceuticals Holding Corp.
Results from added interim analysis of phase III trial of Tonmya (RECOVERY)
Posttraumatic stress disorder,
Early 2020
ASLAN Pharmaceuticals
Interim readout from phase I multiple ascending dose study of ASLAN004
Moderate-severe atopic dermatitis
Q1 2020
Kadmon Holdings LLC
Data from primary analysis of open-label registration trial of KD025 (KD025-213)
Chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy
Q1 2020
Caladrius Biosciences, Inc.
Full results from phase II trial of CLBS16 (ESCaPE-CMD)
Coronary microvascular dysfunction
2020
Precision BioSciences Inc
Initial data from Phase 1/2a clinical trial of PBCAR20A
NHL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)
after Q1 2020
Kala Pharmaceuticals, Inc.
Resubmission of NDA for KPI-121 0.25%
Dry eye disease
after Q1 2020
Reata Pharmaceuticals, Inc.
Top-line data from pivotal phase III trial of Bardoxolone(CATALYST)
Pulmonary arterial hypertension associated with connective tissue disease
Q1 2020
Cocrystal Pharma, Inc.
Top-line results from Hong Kong phase IIa study of CC-31244
Hepatitis C
after Q1 2020
Adverum Biotechnologies Inc.
52-week data from first cohort of phase I study of ADVM-022 (OPTIC)
Wet age-related macular degeneration
after Q1 2020
Adverum Biotechnologies Inc.
24-week data from second cohort of phase I study of ADVM-022 (OPTIC)
Wet age-related macular degeneration (wet AMD)
after Q1 2020
Adverum Biotechnologies Inc.
Submission of IND for ADVM-022
Diabetic retinopathy
after Q1 2020
Trevi Therapeutics
Topline data from phase II/III clinical trial of Nalbuphine ER (PRISM)
Severe pruritus associated with prurigo nodularis
Early 2020
Zealand Pharma A/S
Submission of NDA for Dasiglucagon HypoPal rescue pen
Diabetes patients having a severe hypoglycemic event
2020
Entrx Corporation
Results from phase II study of EB613
Osteoporosis
Q1 2020
Clearside Biomedical, Inc.
Resubmission of NDA for XIPERE
Macular edema associated with non-infectious uveitis
Q1 2020
Seattle Genetics Inc.
Submission of NDA for Tucatinib
Locally advanced unresectable or metastatic HER2-positive breast cancer
Q1 2020
Novavax Inc.
Pivotal phase III data of NanoFlu
Influenza
Q1 2020
ASSEMBLY BIOSCIENCES, INC.
Data from Phase 1b trial of ABI-H2158
HBV
after Q1 2020
Dova Pharmaceuticals, Inc.
Top-line results from phase III trial evaluating the safety and efficacy of DOPTELET
Chemotherapy-induced thrombocytopenia
Q1 2020
NGM Biopharmaceuticals Inc.
24-week Cohort 4 data from phase II study of Aldafermin
NASH
Q1 2020
Ovid Therapeutics Inc.
Data from phase II trial of OV935 (ARCADE)
Dup15q syndrome or CDKL5 Deficiency Disorder
>